Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is entering phase 2.